Get notified of page updates
Glossary on
off
Printer Friendly Page
Retifanlimab Alone or with Other Agents for Advanced Endometrial Cancer that Progressed with Platinum
Clinicaltrials.gov identifier:
NCT04463771
Advanced endometrial cancer
Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)
About the Study
This study is no longer enrolling patients.
This study is for people with advanced or endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of ) alone or in combination with other immunotherapies or targeted therapies.
This Study is Open To:
This study is no longer enrolling patients.
This Study is Not Open To:
This study is no longer enrolling patients.